have showed that ectopic expression of RUNX3 improved CAR‐T cell potency in solid tumour treatment [54] and this finding has been adopted in a phase I clinical trial for HCC patients [55]. The gene discussed is RUNX3; the disease is hepatocellular carcinoma.